不同处理因素对结直肠癌类器官奥沙利铂敏感性测试结果的影响研究

doi:10.3877/cma.j.issn.1674-0793.2021.06.004

目的

选用结直肠癌临床常用药物奥沙利铂，探究不同处理因素对结直肠癌类器官药物敏感性测试结果的影响，为肿瘤患者个体化精准治疗方案的筛选提供测试条件参考。

方法

采用不同细胞密度、给药前不同细胞培养时间、不同药物作用时间对2例结直肠癌类器官CRC51、CRC67进行处理，设计100、10、1、0.1、0.01 μmol/L 5个剂量的奥沙利铂对2例结直肠癌类器官进行作用，CCK-8检测细胞增殖活力，根据细胞存活率（T/C）比较分析不同处理因素对结直肠癌类器官药物敏感性测试结果的影响。

结果

①在细胞密度的选择上，每孔接种8 000个和4 000个细胞时，100 μmol/L的奥沙利铂均对类器官CRC51、CRC67的生长产生显著的抑制作用，两者的抑制作用差异无统计学意义。而每孔接种2 000个细胞时，100 μmol/L的奥沙利铂对类器官CRC51、CRC67的生长抑制作用均显著变弱（与每孔接种8 000个和4 000个细胞相比，P<0.05），药效评价结果变为体外无效。②在给药前细胞培养时间的选择上，没有获得规律性的研究结果，但均T/C>50%。③在药物作用时间的选择上，100 μmol/L的奥沙利铂对类器官CRC51、CRC67作用7 d比作用3 d获得更加显著的生长抑制作用（P<0.05）。

结论

不同细胞密度、给药前不同细胞培养时间、不同药物作用时间对结直肠癌类器官药物敏感性测试结果均会产生影响。选择的实验条件不同，可能会得出相反的药效评价结果。

关键词: 结直肠肿瘤, 类器官, 处理因素, 奥沙利铂, 药物敏感性

Objective

To explore the effects of different processing factors on oxaliplatin sensitivity test results of colorectal cancer organoids and provide reference for the individualized precision treatment for tumor patients.

Methods

Two cases of colorectal cancer organoids were processed with different cell density, different cell culture time prior to administration and different drug action time. Five doses of oxaliplatin were designed to act on the two cases of colorectal cancer organoids. CCK-8 was used to detect cell proliferation activity. The effects of different processing factors on drug sensitivity test results of colorectal cancer organoids were analyzed according to cell survival rate.

Results

In the selection of cell density, 100 μmol/L oxaliplatin could significantly inhibit the growth of colorectal cancer organoids in both cases when inoculated with 8 000 and 4 000 cells per well, and there was no significant difference between the two groups. When inoculated with 2 000 cells per well, the growth inhibitions of 100 μmol/L oxaliplatin on colorectal cancer organoids in both cases were significantly weakened (compared with 8 000 and 4 000 cells per well, P<0.05), and the results of efficacy evaluation became invalid in vitro. No regular results were obtained on the time of cell culture prior to administration. In the choice of time of action, 100 μmol/L oxaliplatin showed more significant growth inhibition effect on the two colorectal cancer organoids after being treated for 7 days than 3 days (P<0.05).

Conclusions

Different cell density, different cell culture time prior to administration and different drug action time show influence on the drug sensitivity test results of colorectal cancer organoids. Different experimental conditions may lead to opposite efficacy evaluation results.

Key words: Colorectal neoplasms, Organoid, Processing factors, Oxaliplatin, Drug sensitivity

图1 不同细胞密度（8 000、4 000、2 000个/孔）对结直肠癌类器官药物敏感性测试结果的影响　A、B分别为CRC51各组T/C百分比柱状图、百分比-对数浓度曲线图；C、F分别为CRC51、CRC67各组结直肠癌类器官处理后形态代表图（×100）；D、E分别为CRC67各组T/C百分比柱状图、百分比-对数浓度曲线图；^***P<0.001，^** P<0.01，^* P<0.05

图2 在相同细胞密度、奥沙利铂作用3 d条件下，给药前不同细胞培养时间（4 h、1 d）对结直肠癌类器官药物敏感性测试结果的影响　A、B分别为CRC51各组T/C百分比柱状图、百分比-对数浓度曲线图；C、F分别为CRC51、CRC67各组结直肠癌类器官处理后形态代表图（×100）；D、E分别为CRC67各组T/C百分比柱状图、百分比-对数浓度曲线图；^* P<0.05

图3 在相同细胞密度、奥沙利铂作用7 d条件下，给药前不同细胞培养时间（4 h、1 d）对结直肠癌类器官药物敏感性测试结果的影响　A、B分别为CRC51各组T/C百分比柱状图、百分比-对数浓度曲线图；C、F分别为CRC51、CRC67各组结直肠癌类器官处理后形态代表图（×100）；D、E分别为CRC67各组T/C百分比柱状图、百分比-对数浓度曲线图；^***P<0.001，^**P<0.01

图4 在相同细胞密度、给药前细胞培养4 h条件下，不同药物作用时间（3、7 d）对结直肠癌类器官药物敏感性测试结果的影响　A、B分别为CRC51各组T/C百分比柱状图、百分比-对数浓度曲线图；C、F分别为CRC51、CRC67各组结直肠癌类器官处理后形态代表图（×100）；D、E分别为CRC67各组T/C百分比柱状图、百分比-对数浓度曲线图；^***P<0.001

图5 在相同细胞密度、给药前细胞培养1 d条件下，不同药物作用时间（3、7 d）对结直肠癌类器官药物敏感性测试结果的影响　A、B分别为CRC51各组T/C百分比柱状图、百分比-对数浓度曲线图；C、F分别为CRC51、CRC67各组结直肠癌类器官处理后形态代表图（×100）；D、E分别为CRC67各组T/C百分比柱状图、百分比-对数浓度曲线图；^**P<0.01

[1]	Xinaris C, Brizi V, Remuzzi G. Organoid models and applications in biomedical research[J]. Nephron, 2015, 130(3): 191-199.
[2]	Fujii M, Shimokawa M, Date S, et al. A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis[J]. Cell Stem Cell, 2016, 18(6): 827-838.
[3]	Usui T, Sakurai M, Enjoji S, et al. Establishment of a novel model for anticancer drug resistance in three-dimensional primary culture of tumor microenvironment[J]. Stem Cells Int, 2016, 2016: 7053872.
[4]	Verissimo CS, Overmeer RM, Ponsioen B, et al. Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening[J]. Elife, 2016, 5: e18489.
[5]	Vlachogiannis G, Hedayat S, Vatsiou A, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers[J]. Science, 2018, 359(6378): 920-926.
[6]	Christenser S, Van Der Roest B, Besselink N, et al. 5-fluorouracil treatment induces characteristic T>G mutations in human cancer[J]. Nat Commun, 2019, 10(1): 4571.
[7]	Cho YH, Ro EJ, Yoon JS, et al. 5-FU promotes stemness of colorectal cancer via p53-mediated WNT/β-catenin pathway activation[J]. Nat Commun, 2020, 11(1): 5321.
[8]	Pauli C, Hopkins B D, Prandi D, et al. Personalized in vitro and in vivo cancer models to guide precision medicine[J]. Cancer Discov, 2017, 7(5): 462-477.
[9]	Schütte M, Risch T, Abdavi-Azar N, et al. Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors[J]. Nat Commun, 2017, 8: 14262.
[10]	van de Wetering M, Francies HE, Francis JM, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients[J]. Cell, 2015, 161(4): 933-945.
[11]	Ng SY, Tan WJ, Pek MMX, et al. Mechanically and chemically defined hydrogel matrices for patient-derived colorectal tumor organoid culture[J]. Biomaterials, 2019, 219: 119400.
[12]	Pinho D, Santos D, Vila A, et al. Establishment of colorectal cancer organoids in microfluidic-based system[J]. Micromachines-Basel, 2021, 12(5): 497.
[13]	Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017[J]. CA Cancer J Clin, 2017, 67(3): 177-193.
[14]	Usui T, Sakurai M, Umata K, et al. Hedgehog signals mediate anti-cancer drug resistance in three-dimensional primary colorectal cancer organoid culture[J]. Int J Mol Sci, 2018, 19(4): 1098.

[1]	雷子威, 凌萍, 沈纵, 魏晨如, 朱邦晖, 伍国胜, 孙瑜. 类器官肺损伤疾病模型构建及应用的研究进展[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 531-535.
[2]	罗青杉, 梅海涛, 郝家领, 蔡锦锋, 周润楷, 温玉刚. 连接蛋白43通过调控细胞周期抑制结直肠癌的增殖机制研究[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 344-349.
[3]	徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[4]	许杰, 李亚俊, 冯义文. SOX新辅助化疗后腹腔镜胃癌D2根治术与常规根治术治疗进展期胃癌的近期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 647-650.
[5]	谢丽春, 欧庆芬, 张秋萍, 叶升. 简化和标准肝脏MRI方案在结直肠癌肝转移患者随访中的临床应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 434-437.
[6]	韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[7]	梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[8]	严虹霞, 王晓娟, 张毅勋. 2 型糖尿病对结直肠癌患者肿瘤标记物、临床病理及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 483-487.
[9]	赵磊, 刘文志, 林峰, 于剑, 孙铭骏, 崔佑刚, 张旭, 衣宇鹏, 于宝胜, 冯宁. 深部热疗在改善结直肠癌术后辅助化疗副反应及生活质量中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 488-493.
[10]	黄海洋, 邝永龙, 陈嘉胜. 基层医院结直肠肿瘤经自然腔道取标本手术30 例分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 510-518.
[11]	张蔚林, 王哲学, 白峻阁, 黄忠诚, 肖志刚. 利用TCGA数据库构建基于miRNA的结直肠癌列线图预后模型[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 381-388.
[12]	张伟伟, 陈启, 翁和语, 黄亮. 随机森林模型预测T1 期结直肠癌淋巴结转移的初步研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 389-393.
[13]	任佳琪, 刁德昌, 何自衍, 张雪阳, 唐新, 李文娟, 李洪明, 卢新泉, 易小江. 网膜融合线导向的脾曲游离技术在左半结肠癌根治术中的应用[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 362-367.
[14]	张迪, 王春霞, 张学东, 李发馨, 庞淅文, 陈一锋, 张维胜, 王涛. 梗阻性左半结直肠癌自膨式金属支架置入后行腹腔镜手术与开腹手术的短期临床疗效比较[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 375-380.
[15]	张津, 李欣达, 徐如祥. 神经类器官在大脑常见疾病治疗中的应用及在脊髓损伤修复中的应用前景[J/OL]. 中华脑科疾病与康复杂志(电子版), 2024, 14(05): 257-263.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Effect of different processing factors on oxaliplatin sensitivity test results of colorectal cancer organoids

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Effect of different processing factors on oxaliplatin sensitivity test results of colorectal cancer organoids